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UK; ###DeB A C K G R O U N D Ischemic heart disease (IHD) is the leading cause of death worldwide. The GBD
(Global Burden of Disease, Injuries, and Risk Factors) study (GBD 2010 Study) conducted a systematic
review of IHD epidemiology literature from 1980 to 2008 to inform estimates of the burden on IHD in
21 world regions in 1990 and 2010.
M E T H O D S The disease model of IHD for the GBD 2010 Study included IHD death and 3 sequelae:
myocardial infarction, heart failure, and angina pectoris. Medline, EMBASE, and LILACS were searched for
IHD epidemiology studies in GBD high-income and low- and middle-income regions published between
1980 and 2008 using a systematic protocol validated by regional IHD experts. Data from included studies
were supplemented with unpublished data from selected high-quality surveillance and survey studies.
The epidemiologic parameters of interest were incidence, prevalence, case fatality, and mortality.
R E S U LT S Literature searches yielded 40,205 unique papers, of which 1,801 met initial screening
criteria. Upon detailed review of full text papers, 137 published studies were included. Unpublished data
were obtained from 24 additional studies. Data were sufﬁcient for high-income regions, but missing or
sparse in many low- and middle-income regions, particularly Sub-Saharan Africa.
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316Ischemic heart disease (IHD) is caused by insuf-
ﬁcient oxygen delivery to meet the metabolic
demands of heart muscle. IHD can be caused by
a failure to adequately perfuse cardiac myocytes
with oxygenated blood (failure of supply) and/or
to increase myocyte oxygen demand [1]. Failure of
oxygen supply most commonly occurs due to a ﬁxed
narrowing or acute rupture or dissection of an
atherosclerotic coronary artery, or less commonly
due to coronary artery spasm, embolism, or vascu-
litis. Inadequate oxygen supply may also occur due
to severe anemia or systemic hypotension. Ischemia
due to increased oxygen demand may be caused by
sustained tachycardia, uncontrolled hypertension,
or heart failure. Less commonly, IHD may occur
due to cardiac revascularization procedures [1].
IHD can lead to acute myocardial necrosis (acute
myocardial infarction [AMI]), fatal arrhythmia, or
to a number of chronic sequelae, most prominently
stable angina pectoris or heart failure (Fig. 1).
IHD was the leading cause of deaths and life-
years lost from any cause worldwide in 2010 [2],
and IHD was the leading cause of death and
disability among the major cardiovascular diseases.
IHD is not only a disease of the elderly in wealthy
countries, but also past analyses by the GBD
(Global Burden of Diseases, Injuries, and Risk
Factors) study and other studies indicate that
IHD has a major global impact on working-age
adults and is a growing problem in low- and
middle-income countries [3e5].
IHD is among the major diseases globally, but
regional importance varies due to differences in
IHD incidence, prevalence, and mortality, as well
as the impact of competing diseases. The GBD
study was started in 1991 as an effort to inform
health policy making by using standard methods
to comprehensively assess the mortality and
disability burden of the world’s major diseases,
injuries, and risk factors by world region for the
year 1990. GBD estimates were updated in 2004
[6], but the current study represents the ﬁrst
comprehensive and de novo analysis since the orig-
inal study. The GBD embarked in 2007 to improve
and update GBD methods and analyze the burden
of diseases, risk factors, and injuries for the years
1990 and 2005 in 21 world regions (Fig. 2) [7].
The latest GBD analysis required comprehensive
and systematic reviews of the epidemiologic litera-
ture for the major global diseases. Here, we present
the methods and summary data for the GBD IHD
epidemiology systematic review. The goals were to:
1) establish GBD case deﬁnitions for IHD and itssequelae; 2) deﬁne an epidemiologic model of
IHD and data types to be included in the review;
3) document the systematic review methods
including novel literature search and validation
strategies; and 4) present the quantity and quality
of the data retrieved.
IHD diagnosis and treatment have changed
since the GBD last gathered primary epidemiologic
data and established its IHD analysis methods.
Most importantly, the universal case deﬁnition of
MI [1,8] evolved to account for widespread use of
biomarkers of MI [9] such as troponins [10] and
creatine kinase-myocardial band mass, and cardiac
imaging in high-income regions [11,12]. In regions
where use of high-sensitivity biomarker measure-
ment became common, many previously undiag-
nosed cases of AMI were identiﬁed. The advent
of troponin measurements needs to be accounted
for when estimating AMI incidence in high-
income nations in 1990 and 2010, but troponin
measurement cannot be required for AMI diagnosis
in regions where troponin measurement is prohibi-
tively expensive and are therefore not
routinely performed [13].
Ongoing event surveillance of a deﬁned popula-
tion is the gold standard for obtaining accurate
population-based IHD incidence and prevalence
estimates. Outside of the MONICA (Multinational
Monitoring of Trends and Determinants in Cardio-
vascular Disease) study [14], and a handful of
similar surveillance studies [15,16], such estimates
have been rare, especially in developing regions.
The GBD Study has developed methods for esti-
mating IHD epidemiologic parameters for regions
with sparse data, but its estimated results will never
substitute for rigorous and direct population surveil-
lance. Therefore, this report will serve not only to
quantify the available body of IHD epidemiologic
research over the >25 years past, but it will also
identify regional gaps in knowledge and highlight
future challenges for global IHD epidemiology
research.
METHODS
GBD 2005 study deﬁnitions of IHD. IHD may result
in death or 3 general chronic sequelae: angina pec-
toris; nonfatal MI; or heart failure (Fig. 1).
IHD death. The International Statistical Classiﬁca-
tion of Diseases and Related Health Problems (ICD)
is the international standard for classifying causes
of death and nonfatal conditions. ICD rules require
identiﬁcation of the disease initiating the causal
Acute MI
death (≤ 1d)
IHD death
(≤ 28d)
Fatal IHD
IHD death
after 28d
Non-IHD
death
No IHD
diagnosis
Incident
IHD
Nonfatal AMI†
(Survive >28d)
Nonfatal 
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Solitary angina
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First or repeat
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Chronic
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Fig. 1. Epidemiologic model of IHD. *Asymptomatic IHD carries no disability weight. Medical therapy or revascularization may partially
alleviate AMI, CHF, or angina symptoms. AMI, acute myocardial infarction; CHF, congestive heart failure; IHD, ischemic heart disease; MI,
myocardial infarction.
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317chain ending in deathsdthat is, the underlying
cause of death. ICD codes identifying IHD as the
underlying cause of death since 1950 were grouped
under the subcategory “cardiovascular and circula-
tory diseases” within the category “noncommunica-
ble diseases” as part of the GBD list of 56 major
causes of death (Table 1). IHD has consistently
been classiﬁed as an underlying cause of death across
multiple revisions of the ICD over time [17]. IHD
deaths typically fall into 1 of 2 broad categories:
death attributable to AMI; and sudden cardiac
deaths. Whereas AMI deaths usually meet
a number of objective diagnostic criteria, many
sudden cardiac deaths are not witnessed and their
association with IHD can only be inferred [14,18].
The ICD also encompasses nonfatal conditions
not meant to be underlying causes of death (e.g.,
essential hypertension) and conditions intermediate
in the causal chain between an underlying cause
and death (e.g., heart failure). When such codes are
inappropriately listed as underlying causes of death
on death certiﬁcates, they are termed “garbage codes”
that need to be reassigned to legitimate underlying
causes of death. Frequent use of garbage codes in
some nations has led to underestimation of IHDmortality rates [19]. The GBD has developed
methods for reallocating garbage codes to legitimate
underlying causes of death [17]. Deaths assigned
nonspeciﬁc cause, signs, and symptoms ICD codes
not meant to represent underlying causes are allo-
cated to legitimate underlying cause codes in propor-
tions equal to the relative magnitude of underlying
cause-, age-, and sex-speciﬁc death rates. For ICD
conditions intermediate in the causal chain between
an underlying cause and death, statistical methods,
literature review, or expert opinion are used to
distribute the garbage-coded deaths to causally asso-
ciated underlying causes. Intermediate causes associ-
ated with IHD deaths are described in Table 1 and
Supplemental Tables 1 and 2. Because IHD is the
most prevalent cause of death worldwide, especially
in older adults, and the biggest proportion of garbage
codes are assigned to deaths in the elderly, a large
proportion of garbage-coded deaths have been real-
located to IHD.
Nonfatal IHD sequelae. AMI is a sudden and sus-
tained loss of perfusion to heart muscle resulting in
cardiac necrosis. Prior GBD analyses followed past
World Health Organization (WHO) MONICA
study criteria [14], which required any 2 of the
Fig. 2. Map of the 21 GBD regions. GBD, Global Burden of Disease, Risk Factors, and Injuries study.
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318following 3 criteria: ischemic symptoms; electrocar-
diographic changes; and elevated serum biomarkers.
Newer biomarkers of cardiac ischemia, especially
troponins, have improved the sensitivity of AMI
diagnosis without a loss in speciﬁcity [9,10]. Another
recent addition to the deﬁnition of AMI is evidence
of perfusion or wall motion abnormalities, which
depends on routine use of cardiac imaging tech-
nology (echocardiography, radionuclide scanning,
angiography, or other technologies). Advances in
AMI diagnostics led recent consensus panels to
recommend a modiﬁed case deﬁnition of AMI based
primarily on abnormal biomarker levels, especially
troponins (Table 2) [1,8,13]. More AMI cases are
diagnosed with the addition of the more sensitive
troponin measures [20e23], leading to an apparent
increase in AMI incidence without a change in the
true incidence [18,24]. Trend analyses need to
correct for the additional AMI diagnosed due to
troponin measures in recent years in high-income
regions [8]. The additional AMI cases identiﬁed
using the new troponin-based criteria, but not
captured by the old criteria may carry a prognosis no
better than “old criteria” AMI, perhaps because the
troponin-only cases occur more often in older
patients with more comorbidities [18].
A potential consequence of an AMI deﬁnition
more dependent on serum biomarkers and imaging(and less dependent on clinical symptoms) is
a widening “diagnosis gap” between high-
diagnostic capacity regions and low-diagnostic
capacity regions. A WHO expert panel recently
acknowledged this problem and proposed a 3-tiered
deﬁnition of AMI (Table 2) [13]. WHO AMI
category A is identical to the troponin-based
European Society of Cardiology/American Heart
Association/World Heart Federation deﬁnition and
was the standard used by the GBD review for
high-income regions. WHO AMI categories B and
C were used as the standard for the GBD review
for low- and middle-income region studies that
lacked the resources necessary for cardiac biomarker
measurement or cardiac imaging. Itwas decided a pri-
ori that GBD IHD analyses would have to adjust
estimates at the individual study level for troponin
measurement status.
The epidemiology of MI is best measured by
capturing AMI cases at the time of diagnosis.
Survey methods used to measure the prevalence of
MI survivors (using self-reported diagnosis or
resting electrocardiograph changes typical of past
MI, especially Q waves) are subject to measurement
error in low-incidence populations and past preva-
lent MI survey studies are of uneven quality [25].
Therefore, MI prevalence survey studies were not
used directly to formulate GBD MI epidemiologic
Table 1. GBD cause of death and sequelae deﬁnitions for IHD
IHD Mortality
GBD Cause of
Death Category
GBD Cause of
Death Subcategory ICD Classiﬁcation
IHD mortality Non-communicable
diseases
Cardiovascular and
circulatory disorders
ICD codes for IHD as underlying cause of death
ICD-10 detail I20eI25
ICD-10 tabulation 1 1,067 (I20eI25)
ICD-9 detail 410e414
ICD-9 tabulationdBTL B270, B278
ICD-8 tabulationdA A083
ICD-7 tabulationdA A081
Categories of garbage-coded deaths frequently
reallocated to IHD as the underlying cause of
death
Deaths assigned nonspeciﬁc symptoms or
signs ICD codes*
Deaths assigned to intermediate causes
associated with IHD as the underlying cause
IHD Sequelae (Disease States) Deﬁnition
AMI
Stable angina pectoris
Congestive heart failure
Deﬁnite and possible AMI according to WHO guidelines (WHO category A, B, or C) (Table 2)
Cases of clinically diagnosed stable exertional angina pectoris or deﬁnite angina pectoris according to
Rose questionnaire (Supplemental Table 1), physician diagnosis, or taking nitrate medication for the
relief of chest pain
Mild or greater symptomatic heart failure (Killip scale k2ek4 [54], NYHA stage IIeIV [35], AHA/ACC
stage C or D [55], or satisfying Framingham heart failure criteria) (Supplemental Table 2). Variable
percentage attributed to IHD, regionally dependent on distribution of IHD as well as other causes of
heart failure.
ACC, American College of Cardiology; AHA, American Heart Association; AMI, acute myocardial infarction; GBD, Global Burden of Disease, Risk Factors, and Injuries
study; ICD, International Statistical Classiﬁcation of Diseases and Related Health Problems; IHD, ischemic heart disease; MI, myocardial infarction; NYHA, New York
Heart Association; WHO, World Health Organization.
* Unspeciﬁed symptoms and signs ICD codes are not meant to be listed as underlying causes of death. Globally, the 20 most prevalent of these codes are ICD-10
R54, R99, R98, I46.9, R09.2, R96.0, I46.1, R68.8, R55, R96.1, N40, G43.9, M19.9, J06.9, R62.8 ,M25.9, G47.3, I46.0, R06, and R00.1 (details, Supplemental Table 1).
 Intermediate causes lie in the causal pathway between the underlying cause and death. ICD-10 intermediate cause codes associated with IHD as the underlying
cause of death are I50, I51, I70, I10, I44, I49, I74, I99, G45.9, G93.1, J81, N17, N18, N19, R07.1, R07.2, R07.3, R07.4, R09.0, R40, R57.0, and R57.9 (details, Supplemental
Table 2).
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319estimates. Silent MI occur without the usual signs
and symptoms of an AMI but are recognized later
using electrocardiography or imaging criteria for
prior MI [26]. Because the GBD intends to quan-
tify only deaths and symptomatic disease states,
the GBD deﬁnition of prior MI excludes silent MI.
Angina pectoris is a pressure-like pain in the
chest induced by exertion or stress and relieved
within minutes after cessation of effort or treatment
with antianginal medications. Stable angina is chest
pain not associated with an acute coronary event
that is induced reliably and reproducibly by the
same level of exertion and is generally managed in
the outpatient setting. Stable angina may be slightly
(approximately 20%) more prevalent in women than
in men internationally [27]. Unstable angina is
a sudden and/or accelerating onset in chest painor new chest pain at rest and represents a clinical
state associated with high risk of AMI and death.
In international registries, unstable angina histori-
cally constitutes approximately one-third to one-
half of acute coronary syndrome presentations, but
unstable angina has declined in use as an “acute
coronary syndrome” category [28]. Subsequent
IHD deaths or nonfatal MI in unstable angina
patients were captured in either of the IHD
mortality or MI categories.
Self-report of chest pain is subjective and there is
no gold standard for estimating angina prevalence in
most population surveys. The Rose questionnaire
(Supplemental Table 3, sometimes referred to as
the London School of Hygiene cardiovascular ques-
tionnaire), has been used as a standard community-
based survey measure of angina prevalence. With
Table 2. GBD case deﬁnitions for AMI, adapted fromWHO 2008 to 2009 consensus panel deﬁnitions (adapted from Mendis et al. [13])
WHO Category A
When there is evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia (no evidence of a cause other than
ischemia). Any 1 of the following criteria meets the diagnosis for MI.
1. Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least 1 value above the 99th percentile of the upper
reference limit together with evidence of myocardial ischemia with at least 1 of the following:
1.1 Symptoms of ischemia;*
1.2 ECG changes indicative of new ischemia (new ST-T changes or new LBBB);
1.3 Development of pathological Q waves in the ECG, including:
a. No unequivocal pathological Q waves in the ﬁrst ECG or in event set of ECG followed by a record with a pathological
Q wave;
or
b. Any Q-wave in leads V2 and V3 0.02 s or QS complex in leads V2 and V3 or Q-wave 0.03 s and 0.01 mV deep or QS complex
in leads I, II, aVL, aVF;
or
c. V4eV6 in any 2 leads of a contiguous lead grouping (I, aVL, V6; V4eV6; II, III, aVF).
1.4 Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
or
2. Sudden (abrupt) unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia;* and
accompanied by
2.1 Presumably new ST-segment elevation or new LBBB;
and/or
2.2 Evidence of fresh thrombus by coronary angiography and/or at autopsy.
But death occurring before blood samples could be obtained or at a time before the appearance of cardiac biomarkers in the blood,
and there is no evidence of a noncoronary cause of death.
or
3. Autopsy ﬁndings of an AMI.
WHO Category B
Whenever there is incomplete information on cardiac biomarkers (preferably troponin) and other diagnostic criteria needed to apply
category A, the term MI should be used if:
Both of the following criteria are present:
1.1 Symptoms of ischemia;* and
1.2 Development of unequivocal pathological Q waves (no pathological Q-wave in the ﬁrst ECG or in the event set of ECG] followed by
a record with a pathological Q-wave);
or
Death with a history of coronary heart disease and/or documented cardiac pain within 72 h before death and no evidence of noncoronary
cause of death, or autopsy evidence of chronic coronary heart disease, including coronary atherosclerosis and myocardial scarring.
WHO Category C
The term “probable MI” should be used when there is insufﬁcient information to decide whether or not there was an MI based on deﬁnitions in
categories A and B, but either 1 of the following is present in a person with symptoms of ischemia,* with no evidence of a noncoronary reason:
1.1 Development of unequivocal pathological Q waves (no pathological Q-wave in the ﬁrst ECG or in the event set of ECG followed by
a record with a pathological Q-wave or development of new ischemia (new ST-T changes§ and an equivocal change in Q wavesjj
demonstrated between the ECG associated with the event or between a previously recorded ECG and the event ECG);
or
1.2 Incomplete information on cardiac biomarkers (preferably troponin) provided that myocardial damage of other reasons and other
clinical conditions that can cause a rise in cardiac biomarkers are excluded.
or
2. Autopsy ﬁndings are suggestive of MI but not conclusive.
aVF, automated volt foot; aVL, automated volt limb; ECG, electrocardiogram(s)/electrocardiography; LBBB, left bundle branch block; other abbreviations as in Table 1.
* Includes various combinations of chest, upper extremity, jaw or epigastric discomfort with exertion or at rest; the discomfort usually lasts 20 min, often is diffuse,
not localized, not positional, not affected by movement of the region, and it may be accompanied by dyspnea, diaphoresis, nausea or syncope.
 Minnesota codes: ST-segment depression: 4.1, 4.2; ST-segment elevation: 9.2; LBBB: 7.1.
 Minnesota codes: 1.1.1 through 1.2.5 plus 1.2.7. Speciﬁcally, any Q-wave in leads V2 andV3 0.02 s (Minnesota code 1.2.1) or QS complex in leads V2 and V3
(Minnesota code 1.2.7). Q-wave 0.03 s and 0.1 mV deep (Minnesota codes 1.1.1, 1.2.2 ) or QS complex in leads I, II, aVL, aVF, or V4eV6 in any 2 leads of
a contiguous lead grouping I, aVL, V6, V4eV6, II, III, aVF (Minnesota codes 1.1.7, 1.3.6).
§ Minnesota codes: 4.1; 4.2; 5.1; 5.2; 9.2.
jj Minnesota code 1.2.8 or any 1.3 code.
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321evidence of inducible myocardial ischemia on exer-
cise electrocardiogram plus nuclear coronary artery
perfusion scanning as the gold standard of angina
diagnosis, the Rose questionnaire has been found
to have 40% to 67% sensitivity and 56% to 80%
speciﬁcity, with markedly lower positive predictive
value in women than in men [29,30]. It has been
proposed that a higher portion of stable angina in
women may be due to impaired coronary microcir-
culation not detectable with conventional coronary
perfusion scans [27]. Nonetheless, because of the
questionable accuracy of the Rose questionnaire,
the GBD also reviewed surveys of physician-
diagnosed angina reported by either the patient
(survey respondent) or the physician. It was decided
a priori that angina prevalence estimates would be
adjusted at the individual study level for angina
measurement method.
Anginal symptoms may be alleviated or dimin-
ished by antianginal medications, most commonly
nitrates, beta-blockers, or calcium channel blockers.
Alternately, anginal symptoms may be treated and
partially or fully relieved by elective revascularization
(i.e., percutaneous coronary interventions or coro-
nary artery bypass graft surgery) (Fig. 1). Past
GBD methods assumed revascularization led to
complete remission of angina. The COURAGE
(Clinical Outcomes Utilizing Revascularization
and Aggressive Drug Evaluation) trial randomized
angina patients to either maximal pharmaceutical
or pharmaceutical therapy plus revascularization
demonstrated that either treatment completely
relieved angina symptoms in at best 60% of patients
in either treatment arm [14], so the present study
assumed that medical management or coronary
revascularization leads to complete remission in
only a corresponding proportion of angina patients.
Heart failure is a chronic long-term sequela for
IHD but may also result from hypertensive heart
disease, valvular heart disease, or cardiomyopathies.
The proportion of heart failure attributed to IHD
as a cause varies by region [31] and has changed
over time within regions [32]. The probability of
developing heart failure after AMI was obtained
from long-term follow-up studies of MI patients
[33,34]. Over the past decades, most epidemiologic
studies have based a diagnosis of heart failure on
the functional classiﬁcation developed by the New
York Heart Association [35], Framingham Heart
Study heart failure criteria [36] (Supplemental
Table 4), or hospital discharge diagnosis ICD code.
Framingham criteria are more rigorous, combining
symptoms and physical examination. The GBDdecided to capture only symptomatic cases of heart
failure meeting Framingham criteria or inclusive of
New York Heart Association class II or higher or
hospitalized cases with heart failure as the principal
discharge diagnosis (ICD-9 428, ICD-10 I50).
Heart failure symptoms may be alleviated by diuretic
and other medications, and survival time with heart
failure can be prolonged by medications (angio-
tensin-converting enzyme inhibitors or angiotensin
receptor blockers, beta-blockers, and others).
An epidemiologic model of IHD. For the purposes of
identifying the main epidemiologic parameters
involved with IHD and the diagnostic measures to
target in the systematic review, we constructed an
epidemiologic model of IHD based on the GBD
deﬁnitions (Fig. 1). Causal arrows in the IHD
model are unidirectional because there was an
assumption that once a diagnosis of IHD is made,
though symptoms may be alleviated, there is no
complete remission to a state of not having IHD.
“Asymptomatic IHD” describes persons who
survived an initial IHD event and are living in an
interval without symptoms of AMI, heart failure, or
angina. Cardiac arrhythmias associated with IHD
that occur outside the setting of AMI were described
and measured by the GBD arrhythmia group and
were not reviewed. As explained herein, some aspects
of IHD are accounted for, but not speciﬁcally
described in the model, such as unstable angina
(because AMI following an episode of unstable
angina would be captured in the model) or silent MI.
The GBD IHD disease model illustrates the
inter-relation between IHD states: for persons in
any given IHD state, there is a probability of tran-
sition to another IHD state (e.g., the probability of
AMI after angina onset or the probability of heart
failure after AMI) and a probability of dying (an
IHD or non-IHD death). Standard relationships
between disease model parameters (incidence, case
fatality, mortality, and prevalence) were incorporated
in a unique GBD software program, DisMod-MR
(Disease Model Meta-Regression; Institute for
Health Metrics and Evaluation, Seattle, WA,
USA). DisMod-MR is particularly useful in
imputing missing or incomplete estimates by ﬁtting
them to known estimates within a disease-speciﬁc
model context. From the epidemiologic model,
a list of the key epidemiologic parameters and study
types were generated (Supplemental Table 5).
Summary methods for the systematic review of IHD
epidemiology studies published from 1980 to
2008. Supplemental Appendix A and Figure 3
describe the systematic review methods in detail.
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322In brief, 3 electronic databases were searched:
MEDLINE (via PubMed), EMBASE, and
LILACS. Searches were initially performed in
MEDLINE and reﬁned there before being adapted
for EMBASE and LILACS. English language and
non-English language articles were included; years
were restricted to 1980 to 2008; articles were limited
to human studies; and no age limits were applied.
The PubMed search was performed using Medical
Subject Heading (MeSH) terms related to IHD,
and additional search terms related to IHD and
IHD sequelae and geographic region terms were
added to the search and restricted to the title or
abstract of the citations. An inclusive, high-
sensitivity approach was employed for low- and
middle-income regions and a restrictive, high-Id
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Fig. 3. Literature review and data abstraction ﬂow chart for IHD syspeciﬁcity approach for high-income regions
(Supplemental Appendix A). MeSH terms “devel-
oped” and “developing” were combined with speciﬁc
country name key words in order to replicate GBD
high-income and low- and middle-income region
groupings. Comparable search strategies were
executed in EMBASE and LILACS.
To validate the initial search strategy, selected
IHD epidemiology experts representing 15 of the
21 GBD regions (Eastern Europe, East Asia, South
Asia, North America, 4 Sub-Saharan Africa regions,
Australasia, Middle East and North Africa, 4 Latin
American regions, and the Caribbean) were asked to
identify key IHD epidemiology papers from their
region(s) of expertise published between January 1,
1980, and July 1, 2008. The initial electronicronic databases, high sensitivity for
ificity for high income regions:
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stematic review. Abbreviations as in Figures 1 and 2.
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validation list of 51 key IHD studies submitted by
the selected experts (Supplemental Appendix B).
The initial search included 71% of the validation
set papers. The initial search strategy was modiﬁed
to include additional search terms identiﬁed in the
expert panel’s papers not retrieved in the ﬁrst search.
The electronic search was repeated in each of the 3
electronic databases, leading to inclusion of 82% of
the experts’ validation list.
Papers were selected for detailed full text review if
the study met all of the following criteria: 1) it re-
ported on an IHD epidemiologic parameter of
interest to the GBD study (incidence, prevalence,
case-fatality, or mortality); 2) it was population-
based; 3) data was reported for an age range including
at least 45 to 54 years; 4) the study observation period
ended after 1980; 5) fatal IHD was deﬁned using
ICD or MONICA coding; and 6) nonfatal IHD
conformed to one of the GBD IHD sequelae deﬁni-
tions. Pairs of study investigators personally reviewed
eligible papers published in English, Spanish, Portu-
guese, or Chinese. Papers published in any other
languages were translated by multilingual health
researchers hired by the GBD study, and the result-
ing translations were reviewed by pairs of study inves-
tigators with the original paper’s results in hand.
Final inclusion or exclusion was based on the criteria
stated herein, and papers were reviewed and dis-
cussed until consensus was reached about inclusion.
Inclusion of selected unpublished IHD epidemi-
ology estimates. The gold standard for most of the
IHD epidemiology estimates needed for the GBD
study is a high-quality IHD surveillance study of
a large, stable, geographically deﬁned population
representative of a GBD region. It was decided
a priori in the interest of parsimony and quality
assurance that epidemiologic estimates for the
North America High Income, Western Europe,
and East Asia regions would be derived primarily
from high-quality surveillance or cohort studies that
span the observation interval of interest (approxi-
mately 1980 until present). To obtain estimates
surrounding the GBD target years of 1990 and
2005, 2 basic observation intervals were identiﬁed
for pooled data: 1985 to 1997 and 1998 to present
or most recent year.
For MONICA study data on IHD death and
MI incidence, the ﬁrst period of observation was
deﬁned as the period of the main MONICA study
(approximately 1983 to 1993). Data after 1994
were contributed by ongoing surveillance studies
that originated in MONICA sites in Sweden (northof country), Finland (FinRISK, national), Belgium
(Ghent), Italy (Brianza), France (Strausbourg, Lille,
and Toulouse), Lithuania (Kaunas), and China
(Beijing, through to 2004) (Supplemental Table 6).
Unpublished U.S. data (the ARIC [Atherosclerosis
Risk in Communities Study], Framingham Heart
Study, Cardiovascular Health Study, and others)
were obtained from the National Heart, Lung, and
Blood Institute (NHLBI) 2006 Chartbook [37].
Published estimates from the Rochester Epidemi-
ology Project [15] and American Heart Association
annual statistics reports [38] were also used. Unpub-
lished national MI incidence data were also provided
for Mexico (A. Lara Esqueda, September 2009), and
Australia (T. Vos, June 2010).
To supplement stable angina prevalence data
(especially for younger adults) and quantify the effect
of different measurement methods on angina preva-
lence estimation, original analyses were conducted
on the international WHS (World Health Survey)
(2002 to 2004) [28], and 3 U.S. surveys: the BRFSS
(Behavioral Risk Factor Surveillance System) (2005
to 2010) [24], the NHANES (National Health
and Nutrition Examination Survey) (2001 to 2002,
2004 to 2009) [31], and theMEPS (Medical Expen-
diture Panel Survey) (2002 to 2009) [39]. Because
the WHS provided angina prevalence data for 47
countries, most of them low- and middle-income
countries, theWHS was a potentially valuable source
of information on the pattern of angina prevalence
worldwide. Information on the surveys and ques-
tionnaire questions used to identify stable angina
cases in these surveys are listed in Supplemental
Appendix C.
For the analysis of ischemic heart failure, hospital
individual record data from Europe (European
Hospital Morbidity Database, 1999 to 2007),
United States (Healthcare Cost and Utilization
Project and National Hospital Discharge Surveys,
1979 to 2006), Canada (Discharge Abstract Data-
base, 2004 to 2009), Mexico (National Health
Information System, 2000 to 2009), Ecuador
(National Statistics Institute Database, 1996 to
2006), and Brazil (Hospital Information System of
the National Uniﬁed Health System, 2006 to
2009) were analyzed to ﬁnd the distribution of
underlying heart failure causes in patients admitted
with the principal diagnosis of heart failure. Addi-
tionally, deaths due to the major underlying causes
of heart failure, as well as cases assigned heart failure
as the cause of death from cause-of-death data, were
used to inform the composition of heart failure
causes.
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The ﬁnal electronic search yielded 40,205 papers,
of which 1,801 initially met inclusion criteria
(Fig. 3). Careful review of full-text papers led to ﬁnal
inclusion of 137 studies (some studies’ results were
reported in more than one publication). Using 2012
World Bank country income categories [40], 114
high-income country studies, 77 middle-income
country studies, and 15 low-income country studies
were included (Supplemental Table 7). For published
studies, 90 originated from high-income countries,
46 from middle-income countries, and one from
low-income countries. All of the low-income coun-
tries studies reported on angina prevalence; there
were no AMI or heart failure studies included from
low-income countries. Despite extensive efforts to
obtain full-text papers from both the Columbia
University and Harvard University libraries and their
afﬁliated collections or directly from regional experts,
a number of publications were unobtainable. Most
remarkably, in the Latin American and Caribbean
regions, 56 full-text papers (3% of all eligible papers)
were not retrievable: 97% of nonretrievable articles
were indexed in LILACS and 78% were published
prior to 1995. Unpublished data from 19 additional
data sources on MI and heart failure epidemiology
were added for the North America,Western Europe,
Eastern Europe, Australasia, Central Latin America,
Tropical Latin America, Andean Latin America, and
East Asia regions. Angina prevalence estimates were
obtained by study investigators for 18 GBD regions
using the U.S. NHLBI 2006 Chartbook and
population-weighted estimates from the WHS,
BRFSS, NHANES, and MEPS surveys.
Sixty-two studies were included for MI incidence
estimation, including 10 unpublished studies. With
the exceptions of Central and Eastern Europe
and East Asia, few good-quality studies on MI
incidence were available representing low- and
middle-income regions (Fig. 4). Especially in
low- and middle-income regions, the majority of
case-fatality studies were single-institution studies
of in-hospital case fatality. Complete in- and out-
of-hospital case fatality was rarely reported
[41e45]. In the end, only 29 studies reporting on
acute MI case fatality were included in the
GBD analysis (Fig. 5).
IHD prevalence surveys were unusually common
in the South Asia, Southeast Asia, Eastern Europe,
and North Africa/Middle East regions. The
systematic review yielded 42 studies reporting on
stable angina prevalence. After adding the NHLBIChartbook data, the WHS and 3 U.S. surveys
analyzed for angina prevalence, led to 47 angina
prevalence studies (Fig. 6). Of 42 heart failure
studies used in the analysis, 9 were unpublished.
Sub-Saharan African regions, especially Central
and East Africa, were remarkable for almost total
lack of IHD epidemiology data of any type. Almost
all of the IHD estimates for Sub-Saharan Africa
came from South Africa. South Africa studies of
IHD epidemiology exclusively in the white popula-
tion (typical of studies published prior to the end of
apartheid) were excluded because they were deemed
not representative of the general population of the
region. Until the advent of recent studies such as
the Heart of Soweto Study [46], studies from
Sub-Saharan Africa were all of low quality or
complicated by uncertainty. For example, the only
2 IHD incidence papers for the entire region repre-
sented the township of Soweto, South Africa. The
ﬁrst incidence paper (Walker and Sareli [47]) did
not state a case deﬁnition for IHD, and for both
incidence estimates, the proportion of cases living
in Soweto and the population of Soweto lack precise
quantiﬁcation [46,47]. The Eastern Europe region
stood out because the majority of studies (75%)
from that region sampled men only.
The only IHD incidence data spanning the years
from approximately 1985 until 2005 using similar
methods over time were gathered from following
studies: 8 ongoing MONICA sites (Fin-MONICA
[now FinAMI], Ghent-MONICA [Belgium], 3
FrenchMONICA sites [Toulouse, Strasbourg, Lille],
Brianza-MONICA[Italy], Sino-MONICA[Beijing,
China], and Kaunas-MONICA [Lithuania]), the
Northern Sweden surveillance study (not part of the
original MONICA study, but employs MONICA
methods), and in the United States, ARIC, the Fra-
mingham Heart Study, the Cardiovascular Health
Study, and the Rochester Epidemiology Project.
Of the AMI incidence studies included, 4 of 7
high-income region studies gathering data after
2000 and reporting detailed diagnostic criteria
included troponin measurements in their MI
outcome diagnostic deﬁnitions. None of the devel-
oping region AMI incidence studies included
positive troponin in the case deﬁnition of AMI.
D I S CU S S I ON
Overview. A systematic review of IHD literature
in 21 world regions demonstrated that it is feasible
to gather IHD epidemiology literature using
a high-sensitivity approach for developing regions
Fig. 4. Number of included studies used for myocardial infarction incidence estimation, by GBD region. GBD, Global Burden of Disease,
Risk Factors, and Injuries study.
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regions. Despite this design, the review revealed
scant IHD epidemiology data from most low- and
middle-income regions, particularly Sub-Saharan
Africa. In contrast, complete high-quality esti-
mates were available from East Asia and Central
Europe, which are on average middle-income
regions. Even for high-income regions, most of
the comprehensive estimates including the years
surrounding 1990 and 2005 were gathered from
unpublished data. From this review of IHDFig. 5. Number of included studies used for acute myocardial infarct
Disease, Risk Factors, and Injuries study.epidemiology, a number of key methodologic
challenges were identiﬁed: the need to reallocate
IHD deaths erroneously assigned to ill-deﬁned
cardiovascular causes, the need to adjust past
incidence to ﬁt with the new, troponin-based
deﬁnition of AMI, measurement limitations of
population survey estimation of stable angina and
IHD prevalence, estimation of the fraction of all
heart failure attributable to IHD and the more
general problems of missing data, random error,
and bias.ion case fatality estimation, by GBD region. GBD, Global Burden of
Fig. 6. Number of included studies used for stable angina pectoris prevalence estimation, by GBD region. GBD, Global Burden of
Disease, Risk Factors, and Injuries study.
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326IHD death. Effective allocation of global public
health resources depends on accurate vital statistics,
including national cause-of-death data. The
problem of “bridging” cause-of-death data across
changing ICD deﬁnitions has been simpliﬁed by
creating a list of GBD 291 major causes of death.
GBD investigators have been able to consistently
trace IHD as an underlying cause of death from the
earliest ICD up until the current ICD-10. Frequent
use of garbage codes may bias cause-speciﬁc
mortality rates. In particular, past studies have
shown that IHD death rates are substantially
underestimated for some nations if garbage-coded
deaths are not accounted for [19]. The GBD has
recently reﬁned the method for reallocating
garbage-coded deaths to IHD and other underlying
causes [17], ensuring optimal use of available
national cause-of-death data for the purpose of
estimating the mortality portion of the global
burden of IHD.
AMI. The recommended case deﬁnition of AMI
was recently changed to include a primary emphasis
on positive biomarker measurements, speciﬁcally
troponin [1]. Troponin measurements were intro-
duced in high-income nations during the mid-
1990s. We found no low- or middle-income
region studies of AMI incorporating positive
troponin in the case deﬁnition published during
1980 to 2008. Even in high-income regions, the
troponin-based deﬁnition of MI has been used in
epidemiologic studies only since approximately
2000. Moving forward, in comparing past AMIincidence estimates to estimates after 2000, past
estimates will require adjustment to reﬂect the
additional incidence that would have been added
had troponin been available [48,49]. The GBD
main epidemiologic and burden estimates will
adjust AMI incidence using a study-level troponin
measurement variable for data published after
approximately 2000. Regarding MI case fatality,
numerous published single-center studies of
in-hospital case fatality were identiﬁed, but
population-based and multicenter studies were rare,
leading to only 29 AMI case-fatality studies
included in the analysis; 15 of these were from low-
or middle-income regions.
Angina pectoris. The primary GBD angina case
deﬁnition relies on the classic Rose questionnaire
descriptions, but studies included from the systematic
review employed a variety of measures of angina prev-
alence, including self-reported diagnosis, diagnosis
made by a study physician, and even use of speciﬁc
antianginal medications (e.g., nitrates). Several
studies suggest that the Rose questionnaire has poor
speciﬁcity, especially in women (range 56% to 76%)
[29,50,51], leading to inﬂated prevalence estimates in
women than inmen. Others argue that higher angina
prevalence in women than in men persists when
a more rigorous diagnostic method is used [52], and
Rose-diagnosed angina implies a poor prognosis and
should not be dismissed by clinicians or epidemiol-
ogists [27]. Based on the review literature, we
concluded that angina prevalence estimation should
account for measurement method and that lack of
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preting estimates of angina prevalence.
Ischemic heart failure. IHD is only one of several
causes of heart failure in the GBD. Estimation of
ischemic heart failure prevalence required a 2-step
process: 1) estimating the total heart failure enve-
lope, inclusive of heart failure cases of all causal
origins; and 2) estimating the proportion of heart
failure attributable to IHD speciﬁc to region, age
group, and sex. Data from the systematic review
were included in both steps of the analysis.
Study limitations. Though this systematic review
conformed to most of the standard guidelines
for systematic reviews (PRISMA checklist
Supplemental Appendix D) [53], it is possible that
many of the included studies reported data collected
with bias, and for many estimates, no measures of
uncertainty (in the form of standard deviations or
errors, conﬁdence intervals, etc.) were reported.
Though many of the studies contributing data to the
GBD review were population-based studies or
national cause-of-death or hospital registries, some
may not be regionally representative. In some
instances, national or provincial surveys or cohort
studies were selected that may fail to accurately
represent an epidemiologically heterogeneous
regional population. A study of national IHD
mortality trends in several selected world regions
demonstrated that there may be variability within
broad geographic regions [54]. Some of this variance
may be due to methodologic differences in vital
statistics registration, but some may be due to
epidemiologic heterogeneity that is obscured when
reporting estimates for broad regions. Especially for
publications from the LatinAmerican andCaribbean
region papers published before 1995, a substantial
proportion of published papers selected for review
were not obtainable. Selected unpublished data were
obtained, but these predominantly represent high-
income regions. It is likely that we are missing
a great deal of unpublished data from government
and large health system records; it was beyond the
scope of this review to quantify the volume of
unpublished data missed by using standard electronic
database search methods.
CONC LU S I ON S
Health policy decisions and resource allocation
are ideally made based on high-quality epidemio-
logic data. The scale and pervasiveness of IHD
in the majority of world regions makes estimationof IHD mortality, incidence, prevalence, and case
fatality crucially important to public health world-
wide. A main objective of the GBD is provision of
accurate, unbiased estimates of disease burden
gathered and analyzed with standard methods
and reported with transparency. This GBD
systematic review of IHD demonstrated that it is
feasible to complete a large-scale review of the
IHD epidemiology literature using search methods
tailored to emphasize sensitivity in developing
regions and speciﬁcity in high-income regions.
Despite this broad search and careful screening,
the quantitative results of the review demonstrate
the scarcity of high-quality IHD epidemiologic
data to support policy making and resource alloca-
tion, particularly in low- and middle-income
regions. Assessment of qualitative results of the
IHD epidemiology review leads to the conclusion
that there is no substitute for high-quality, stan-
dardized surveillance studies of IHD. Ongoing
surveillance studies deserve support, and the
founding of new surveillance studies should be
a high priority, especially in low- and middle-
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